Non-viral and mRNA-based strategies for next-generation CAR-T cell therapy

Area of Science:

• Cellular immunotherapy
• Biotechnology
• Molecular engineering

Background:

• Chimeric antigen receptor (CAR)-T cell therapy shows promise for hematologic malignancies but faces limitations like cost, complexity, and viral vector risks.
• Expanding CAR-T applications to solid tumors and autoimmune diseases necessitates overcoming current manufacturing and delivery challenges.
• Advancements in mRNA therapeutics and non-viral delivery systems are progressing, but a unified approach for CAR-T engineering is needed.

Purpose of the Study:

• To explore the integration of mRNA engineering with non-viral delivery platforms for CAR-T cell generation.
• To provide a unified translational perspective on non-viral mRNA-based CAR-T engineering.
• To identify barriers and opportunities for clinical translation of next-generation cell therapies.

Main Methods:

• Review of current literature on mRNA engineering and non-viral delivery systems (lipid nanoparticles, electroporation, exosomes).
• Analysis of strategies for ex vivo and in vivo CAR-T generation using mRNA and non-viral platforms.
• Discussion of computational approaches for optimizing mRNA sequences and delivery carriers.

Main Results:

• mRNA engineering combined with non-viral delivery offers a potentially safer and more flexible alternative to viral vectors for CAR-T generation.
• Integration facilitates both ex vivo and in vivo CAR-T generation, expanding therapeutic possibilities.
• Computational methods are emerging as crucial tools for optimizing mRNA-based cell therapies.

Conclusions:

• Non-viral mRNA-based CAR-T engineering presents a practical framework for developing advanced cell therapies.
• Addressing challenges in expression durability, cell-specific delivery, scalability, and regulatory pathways is key for clinical translation.
• This integrated approach is vital for advancing cell therapies beyond current limitations.